Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motixafortide and Natalizumab for HSC Mobilization in SCD
NCT05618301Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Jul 2023
- Primary completion
- Jun 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of motixafortide in sickle cell disease (SCD), sponsored by Washington University School of Medicine. Started Jul 2023; status: completed.
02
Drugs
motixafortide
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05618301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05618301.